Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BL-1020

Known as: BL 1020, BL1020 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Background/aims Cognitive impairment, which frequently occurs in patients with schizophrenia, bipolar disorder, Alzheimer’s… Expand
Is this relevant?
Review
2016
Review
2016
  • Danish Mahmood
  • International journal of health sciences
  • 2016
  • Corpus ID: 10215687
Histamine H3 receptors are present as autoreceptors on histaminergic neurons and as heteroreceptors on nonhistaminergic neurones… Expand
Is this relevant?
2012
2012
OBJECTIVE BL-1020 is a γ-aminobutyric acid (GABA)-enhanced antipsychotic that combines dopamine antagonism with GABA agonist… Expand
Is this relevant?
Review
2010
Review
2010
In schizophrenia, a psychiatric disorder that affects approximately 1% of the global population and is associated with… Expand
Is this relevant?
2010
2010
BACKGROUND BL-1020, a novel gamma aminobutyric acid (GABA) ester of perphenazine, is a new oral antipsychotic with a strong… Expand
Is this relevant?
2010
2010
Background: BL-1020 is a new chemical entity that combines dopamine antagonism with GABAergic activity. PK studies demonstrate… Expand
Is this relevant?
2009
2009
UNLABELLED Reduced brain gamma-amino-butyric acid (GABA) participates in the pathogenesis of schizophrenia. GABA scarcely… Expand
Is this relevant?
2009
2009
BL-1020 is a potentially novel antipsychotic, which comprises the typical antipsychotic perphenazine linked by an ester bound to… Expand
Is this relevant?
2009
2009
BL-1020 is a potentially novel antipsychotic, which comprises the typical antipsychotic perphenazine linked by an ester bound to… Expand
Is this relevant?